You are viewing the site in preview mode
Skip to main content
|
Variable
|
n = 413
|
|---|
|
Age, yearsa
|
75.6 (12.4)
|
|
Femalec
|
176 (42.6)
|
|
Weight, kgb
|
72.5 (64.5–82)
|
|
Hypertensionc
|
295 (71.4)
|
|
Type 2 diabetesc
|
112 (27.1)
|
|
Dyslipidemiac
|
201 (48.7)
|
|
eGFR < 45 mL/min/1.73 m2 c
|
39 (9.5)
|
|
Antiplatelet therapyc
|
129 (31.2)
|
|
Anticoagulant therapyc
|
86 (20.8)
|
|
SBP at admission, mmHgb
|
152 (135–171)
|
|
DBP at admission, mmHgb
|
82 (73–93)
|
|
Serum glucose at admission, mg/dLb
|
113 (99.5–142)
|
|
Neutrophil count at admission, × 109/Lb
|
5.2 (4.1–6.7)
|
|
Lymphocyte count at admission, × 109/Lb
|
1.8 (1.3–2.4)
|
|
Baseline NIHSS scoreb
|
6 (3–15)
|
|
ASPECTS < 7c
|
16 (4.01)
|
|
ASPECTS, pointsa
|
9.45 (1.24)
|
|
Baseline mRS scorec
|
|
mRS 0
|
164 (39.8)
|
|
mRS 1
|
125 (30.3)
|
|
mRS 2
|
74 (18.0)
|
|
mRS 3
|
32 (7.8)
|
|
mRS 4
|
17 (4.1)
|
|
Etiologic subtype by TOASTc
|
|
LAA
|
43 (10.4)
|
|
SVO
|
62 (15.0)
|
|
Cardioembolic stroke
|
178 (43.1)
|
|
Undetermined
|
123 (29.8)
|
|
Other causes
|
7 (1.7)
|
|
Posterior circulation strokec
|
55 (13.3)
|
|
Intravenous thrombolysisc
|
151 (36.6)
|
|
Endovascular treatmentc
|
70 (17.0)
|
|
Hemorrhagic transformationc
|
51 (12.4)
|
|
3-month mortalityc
|
67 (17.1)
|
|
3-month functional independencec
|
227 (57.9)
|
- SD standard deviation, IQR interquartile range (denoted by 25th–75th percentile), eGFR estimated glomerular filtration rate, SBP systolic blood pressure, DBP diastolic blood pressure, NIHSS National Institute of Health Stroke Scale, ASPECTS Alberta Stroke Program Early CT Score, mRS modified Rankin Scale, LAA large-artery atherosclerosis, SVO small-vessel occlusion
- aContinuous variables with normal distributions are presented as means (SD)
- bContinuous non-normally distributed variables are presented as medians (IQR)
- cCategorical variables are presented as n (%)
